Previous 10 | Next 10 |
CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapies (DMTs) No appr...
Clene press release ( NASDAQ: CLNN ): Q3 GAAP EPS of -$0.17 beats by $0.05 . Revenue of $0.17M (+54.5% Y/Y) beats by $0.1M . Clene’s cash, cash equivalents and marketable investments securities totaled $16.2 million as of September 30, 2022, compared to ...
Secondary survival endpoint for the CNM-Au8 ® 30 mg dose investigated in the Healey ALS Platform Trial demonstrated a >90% reduction in the risk of death or death equivalent (permanently assisted ventilation) and risk of death alone at 24 weeks . This survival be...
Clene ( NASDAQ: CLNN ) and its wholly owned subsidiary Clene Nanomedicine has entered into a securities purchase agreement with certain existing stockholders for the purchase and sale of 10.72M shares of the Co.’s common stock at a purchase price/share of $1.01, pr...
SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative d...
Microcap biotech Clene Inc. ( NASDAQ: CLNN ) fell ~13% premarket Monday after the company announced that its lead candidate CNM-Au8 did not reach the primary endpoint in a placebo-controlled study involving patients with amyotrophic lateral sclerosis (ALS), a rare neurolog...
The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeks Prespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently ass...
Cheap Stocks To Buy [or avoid] Want to make money trading in the stock market today and use penny stocks to do it? Be prepared for volatility. Not only are cheap stocks increasingly volatile, but so is the stock market today, in general. With so much concern abuzz about the stock market...
SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerati...
Treatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomization Comparable survival benefits were also shown compared to ENCALS predicted median survival C ...
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...